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Abstract
There is a need to identify patients who may beneﬁt from particular treatments. We investigated prognosis in
915 patients with mCRC from 2 phase III trials of panitumumab plus chemotherapy, based on Köhne category
and BRAF status. Both Köhne category and BRAF status predicted outcomes in terms of PFS and OS, and
panitumumab provided beneﬁts over chemotherapy alone.
Background: Köhne prognostic score is used to classify patients with metastatic colorectal cancer (mCRC) as high,
intermediate, or low risk. Using data from 2 phase III trials, we analyzed survival in patients categorized according to
Köhne prognostic category and virus-induced rapidly accelerated ﬁbrosarcoma murine sarcoma viral oncogene ho-
molog B (BRAF) mutation. Patients and Methods: PRIME (Panitumumab Randomized Trial In Combination With
Chemotherapy for Metastatic Colorectal Cancer to Determine Efﬁcacy) (ﬁrst-line) and 20050181 (second-line) were
studies of chemotherapy with or without panitumumab. Progression-free survival (PFS) and overall survival (OS) were
analyzed retrospectively in rat sarcoma viral oncogene homolog (RAS) wild type (WT) and RAS WTþBRAF WT mCRC
in each Köhne category, and in BRAF mutant (MT) mCRC. Results: In PRIME (n ¼ 495) and 20050181 (n ¼ 420), 53
(11%) and 44 (10%) patients, respectively, had BRAF MT mCRC. Of the RAS WTþBRAF WT/unknown populations,
85/267/90 and 82/211/83 were categorized as high/medium/low risk, respectively. PFS and OS hazard ratios (HRs),
adjusted for Köhne group, for patients with RAS WT þ BRAF WT/unknown mCRC favored panitumumab with
chemotherapy versus chemotherapy alone in both studies. In PRIME, the PFS HR was 0.74 (95% conﬁdence interval
[CI], 0.61-0.90) and OS HR was 0.78 (95% CI, 0.64-0.95). In 20050181, PFS and OS HRs were 0.80 (95% CI, 0.65-
0.99) and 0.78 (95% CI, 0.62-0.99), respectively. Median PFS and OS were lower in patients with BRAF MT mCRC
than in any of the 3 risk categories for patients with RAS WTþBRAF WT/unknown mCRC. Conclusion: During ﬁrst-
and second-line treatment, Köhne prognostic score allows accurate risk classiﬁcation in RAS WT mCRC. BRAF MT
mCRC should be classiﬁed as high risk regardless of other parameters. Panitumumab with chemotherapy might
provide survival beneﬁts versus chemotherapy alone in RASWT and RASWTþBRAFWT/unknown mCRC, overall and
across risk categories.
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Introduction
Survival outcomes in patients with metastatic colorectal cancer
(mCRC) differ widely depending on their disease characteristics
at the start of treatment. Furthermore, the choice of ﬁrst- and
second-line treatment is generally made on the basis of patient and
disease characteristics, treatment goal (eg, resection or disease con-
trol), and rat sarcoma viral oncogene homolog (RAS) status.1 Thus
there is a need to deﬁne patient subgroups who will derive the most
beneﬁt from speciﬁc treatments. An analysis of data from 3825 pa-
tients with mCRC showed that they can be divided into 3 prognostic
categories (high, medium, and low risk) on the basis of 4 baseline
clinical parameters2: Eastern Cooperative Oncology Group (ECOG)
performance status, white blood cell count, alkaline phosphatase
levels, and number of metastatic sites. The importance of these pa-
rameters has been conﬁrmed in studies of regimens including oxa-
liplatin and irinotecan combinations.3,4 More recently, mutations in
the virus-induced rapidly accelerated ﬁbrosarcoma murine sarcoma
viral oncogene homolog B (BRAF) gene have also been identiﬁed as a
negative prognostic marker in mCRC.5-9
Epidermal growth factor receptor (EGFR) inhibitors are an
important treatment option for patients with mCRC.1,10 These
agents are licensed only for patients whose tumors have wild type
(WT) RAS genes (KRAS and NRAS ), because RAS mutations result
in a lack of response to EGFR inhibitors.11-15 Several phase III trials
have shown the efﬁcacy and tolerability of the EGFR inhibitor
panitumumab in patients with RAS WT mCRC.16 For example,
results from the ﬁrst-line PRIME (Panitumumab Randomized Trial
In Combination With Chemotherapy for Metastatic ColorectalTable 1 Progression-Free Survival and OS in Patients With RAS Wild
in the PRIME and 20050181 Studies
Risk Category KaplaneMeier Median PFS, Months (95%
PRIME Study
Panitumumab and
FOLFOX4
FOLFOX4
High n ¼ 46
6.3 (4.8-12.1)
n ¼ 51
7.6 (4.4-11.
HR, 0.89; 95% CI, 0.59-1.35
Medium n ¼ 146
12.5 (9.7-14.9)
n ¼ 151
8.6 (7.3-9.9
HR, 0.66; 95% CI, 0.52-0.85
Low n ¼ 54
10.8 (9.3-17.1)
n ¼ 46
9.5 (7.0-11.
HR, 0.79; 95% CI, 0.51-1.20
20050181 Study
Panitumumab and
FOLFIRI
FOLFIRI
High n ¼ 42
6.1 (4.1-9.3)
n ¼ 50
3.6 (2.5-5.3
HR, 0.68; 95% CI, 0.44-1.07
Medium n ¼ 125
6.9 (5.5-8.3)
n ¼ 110
5.5 (3.9-6.8
HR, 0.91; 95% CI, 0.69-1.21
Low n ¼ 40
7.5 (5.9-11.2)
n ¼ 52
5.7 (3.7-7.3
HR, 0.51; 95% CI, 0.31-0.85
Abbreviations: FOLFIRI ¼ leukovorin, 5-ﬂuorouracil, and irinotecan; FOLFOX4 ¼ leukovorin, 5-ﬂuoro
survival; PFS ¼ progression-free survival; PRIME ¼ Panitumumab Randomized Trial In CombinationCancer to Determine Efﬁcacy) study showed that panitumumab
signiﬁcantly improved overall survival (OS) when combined with
leucovorin, 5-ﬂuorouracil, and oxaliplatin (FOLFOX4) versus
FOLFOX4 alone.8 In the second-line 20050181 study, pan-
itumumab with leucovorin, 5-ﬂuorouracil, and irinotecan (FOL-
FIRI) signiﬁcantly improved progression-free survival (PFS) versus
FOLFIRI alone in patients with RAS WT mCRC.17 Using data
from the PRIME and 20050181 studies, we retrospectively analyzed
survival outcomes in patients with mCRC categorized according to
Köhne prognostic category and BRAF mutation status.
Patients and Methods
Study Design
The PRIME (ClinicalTrials.gov: NCT00364013) and 20050181
(NCT00339183) were international, open-label phase III studies in
which patients were randomized (1:1) to receive FOLFOX4
(PRIME) or FOLFIRI (20050181) with or without panitumumab.
Full details of these studies have been published previously.18,19
In brief, eligible patients were adults with metastatic adenocarci-
noma of the colon or rectum, and an ECOG performance status of
0 to 2. In PRIME, patients were previously untreated, whereas those
in 20050181 had previously progressed while receiving, or within 6
months of, 1 previous ﬂuoropyrimidine-based mCRC therapy. In
both studies, panitumumab was administered as an intravenous
infusion of 6.0 mg/kg on the ﬁrst day of each 14-day cycle.
The present analysis focused on patients with RAS WT mCRC
(ie, tumors WT for KRAS/NRAS exon 2 [codons 12 and 13], exon 3
[codons 59 and 61], and exon 4 [codons 117 and 146]).8,17 In bothType mCRC Categorized According to Köhne Prognostic Category
CI) KaplaneMeier Median OS, Months (95% CI)
Panitumumab and
FOLFOX4
FOLFOX4
4)
n ¼ 46
13.9 (7.4-21.2)
n ¼ 51
15.1 (10.6-17.6)
HR, 0.91; 95% CI, 0.60-1.39
)
n ¼ 146
29.8 (23.9-32.8)
n ¼ 151
21.7 (17.4-25.3)
HR, 0.70; 95% CI, 0.55-0.91
1)
n ¼ 54
35.6 (22.5-45.0)
n ¼ 46
26.9 (19.1-40.4)
HR, 0.76; 95% CI, 0.48-1.21
Panitumumab and
FOLFIRI
FOLFIRI
)
n ¼ 42
11.2 (7.9-16.1)
n ¼ 50
9.2 (5.7-12.8)
HR, 0.76; 95% CI, 0.48-1.21
)
n ¼ 125
16.6 (14.3-20.1)
n ¼ 110
13.6 (10.8-19.6)
HR, 0.89; 95% CI, 0.64-1.23
)
n ¼ 40
23.8 (16.2-28.1)
n ¼ 52
16.6 (14.8-23.7)
HR, 0.63; 95% CI, 0.35-1.12
uracil, and oxaliplatin; HR ¼ hazard ratio; mCRC ¼ metastatic colorectal cancer; OS ¼ overall
With Chemotherapy for Metastatic Colorectal Cancer to Determine Efﬁcacy.
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Table 2 Progression-Free Survival and OS in BRAF Wild Type/Unknown mCRC Categorized According to Köhne Prognostic Category,
and BRAF Mutant mCRC in the PRIME and 20050181 Studies
Risk Category KaplaneMeier Median PFS, Months (95% CI) KaplaneMeier Median OS, Months (95% CI)
PRIME Study
Panitumumab and
FOLFOX4
FOLFOX4 Panitumumab and
FOLFOX4
FOLFOX4
BRAF Wild Type/Unknown
High n ¼ 38
8.3 (5.8-13.8)
n ¼ 47
7.8 (5.3-11.4)
n ¼ 38
16.7 (10.5-21.9)
n ¼ 47
15.1 (10.6-20.2)
HR, 0.79; 95% CI, 0.50-1.24 HR, 0.83; 95% CI, 0.53-1.30
Medium n ¼ 136
12.6 (9.7-15.4)
n ¼ 131
9.3 (7.7-11.0)
n ¼ 136
30.4 (25.4-36.1)
n ¼ 131
23.6 (18.4-27.7)
HR, 0.70; 95% CI, 0.54-0.90 HR, 0.71; 95% CI, 0.54-0.93
Low n ¼ 49
10.9 (9.4-17.7)
n ¼ 41
9.9 (7.2-12.9)
n ¼ 49
40.0 (22.5-47.4)
n ¼ 41
35.2 (23.1-46.8)
HR, 0.81; 95% CI, 0.52-1.28 HR, 0.79; 95% CI, 0.48-1.29
BRAF Mutant
Overall n ¼ 24
6.0 (3.5-10.7)
n ¼ 29
5.4 (3.3-6.2)
n ¼ 24
10.4 (5.6-18.9)
n ¼ 29
9.2 (7.5-15.7)
HR, 0.74; 95% CI, 0.42-1.29 HR, 0.97; 95% CI, 0.55-1.69
20050181 Study
Panitumumab and
FOLFIRI
FOLFIRI Panitumumab and
FOLFIRI
FOLFIRI
BRAF Wild Type
High n ¼ 38
7.4 (5.2-9.4)
n ¼ 44
3.7 (2.8-5.6)
n ¼ 38
13.3 (8.1-19.0)
n ¼ 44
11.1 (5.7-14.5)
HR, 0.68; 95% CI, 0.42-1.09 HR, 0.78; 95% CI, 0.47-1.28
Medium n ¼ 111
7.4 (6.1-8.7)
n ¼ 100
5.6 (3.9-6.9)
n ¼ 111
18.7 (15.2-21.5)
n ¼ 100
15.9 (12.1-22.9)
HR, 0.87; 95% CI, 0.65-1.18 HR, 0.89; 95% CI, 0.63-1.26
Low n ¼ 37
7.5 (5.9-11.2)
n ¼ 46
5.9 (4.6-7.5)
n ¼ 37
23.8 (16.5-28.1)
n ¼ 46
18.4 (15.1-23.8)
HR, 0.53; 95% CI, 0.31-0.90 HR, 0.67; 95% CI, 0.36-1.23
BRAF Mutant
Overall n ¼ 21
2.6 (1.7-3.7)
n ¼ 23
1.9 (1.8-3.7)
n ¼ 21
4.8 (2.8-9.8)
n ¼ 23
5.7 (3.2-7.3)
HR, 1.04; 95% CI, 0.56-1.94 HR, 0.74; 95% CI, 0.39-1.39
Abbreviations: FOLFIRI ¼ leukovorin, 5-ﬂuorouracil, and irinotecan; FOLFOX4 ¼ leukovorin, 5-ﬂuorouracil, and oxaliplatin; HR ¼ hazard ratio; mCRC ¼ metastatic colorectal cancer; OS ¼ overall
survival; PFS ¼ progression-free survival; PRIME ¼ Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efﬁcacy.
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52 -studies, KRAS exon 2 testing was performed in a blinded central
laboratory using allele-speciﬁc polymerase chain reaction (DxS Ltd,
Manchester, United Kingdom).18,19 RAS mutations beyond KRAS
exon 2 were detected using bidirectional Sanger sequencing (both
studies) and using WAVE-based Surveyor Scan Kits (Transgenomic
Inc, Omaha, NB; PRIME only) in WT KRAS exon 2 tumor spec-
imens.8,17 Patients were characterized as having RASmutations if any
predeﬁned activating mutation in KRAS or NRAS was detected.
Patients were also categorized on the basis of BRAFmutation status
(exon 15 [V600E]), assessed using bidirectional Sanger sequencing in
WT KRAS exon 2 tumor specimens (both studies) and using WAVE-
based SURVEYOR Scan Kits (Transgenomic Inc; PRIME only).8,17
Survival Analysis
Progression-free survival and OS were analyzed retrospectively for
the overall RASWT population for each Köhne prognostic category,
established on the basis of data from before the previous ﬁrst-lineClinical Colorectal Cancer March 2018therapy was started. In a second analysis, patients with BRAF
mutant (MT) mCRC were analyzed separately, with the remaining
patients then analyzed according to Köhne prognostic category (see
Supplemental Figure 1 in the online version). For the purposes of
this analysis, patients from PRIME with unknown BRAF status
were grouped together with patients who had BRAF WT tumors,
although a separate analysis was conducted in which patients with
unknown BRAF status were excluded.
For PRIME, the analysis was conducted when 80% of patients
enrolled in the study had died. For 20050181, the primary analysis
data cutoff (380 PFS events) was used. Survival was analyzed using
the KaplaneMeier method and presented as median (95% conﬁ-
dence interval [CI]) values. Hazard ratios (HRs) for PFS and OS in
the panitumumab with FOLFOX4 arm versus the FOLFOX4-alone
arm, and the panitumumab with FOLFIRI arm versus the FOLFIRI-
alone arm, were calculated using a Cox proportional hazards model.
All of the analyses were exploratory and descriptive in nature.
Figure 1 KaplaneMeier Curves for Overall Survival in Patients in the PRIME (Panitumumab Randomized Trial in Combination With
Chemotherapy for Metastatic Colorectal Cancer to Determine Efﬁcacy) Study With BRAF Wild Type/Unknown Metastatic
Colorectal Cancer (mCRC) Categorized According to Köhne Prognostic Group, and for Patients With BRAF Mutant mCRC
Overall, in the (A) Panitumumab With FOLFOX4, and (B) FOLFOX4-Alone Arms
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Abbreviation: FOLFOX4 ¼ leukovorin, 5-ﬂuorouracil, and oxaliplatin.
Salvatore Siena et alResults
Patients
Of 1183 patients enrolled in PRIME, 505 (43%) had RAS WT
mCRC, of whom 494 (98%) had sufﬁcient data for a Köhne
prognostic category to be established, with 97, 297, and 100 pa-
tients categorized as high, medium, and low risk, respectively. Of
1186 patients enrolled in the 20050181 study, 421 had RAS WT
mCRC, of whom 419 (>99%) had sufﬁcient data for a Köhne
prognostic category to be established, with 92 high-risk, 235
medium-risk, and 92 low-risk patients.Of the 505 patients in PRIME with RAS WT mCRC, tumors
from 53 patients (11%) were categorized as BRAF MT (see
Supplemental Figure 2 in the online version). BRAF status was
unknown in 13 patients (3%); these were grouped alongside pa-
tients with BRAF WT status for the purposes of the analysis. The
remaining RAS WTþBRAF WT/unknown analysis included 85,
267, and 90 patients categorized as high, medium, and low risk,
respectively. In the 20050181 study, BRAF status was known for all
patients, and tumors from 44 (10%) of the 421 patients with RAS
WTmCRC were categorized as BRAFMT, including 1 patient whoClinical Colorectal Cancer March 2018 - 53
Figure 2 KaplaneMeier Curves for Overall Survival in Patients in the 20050181 Study With BRAF Wild Type Metastatic Colorectal
Cancer (mCRC) Categorized According to Köhne Prognostic Group, and for Patients With BRAF Mutant mCRC Overall, in the
(A) Panitumumab With FOLFIRI, and (B) FOLFIRI-Alone Arms
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Abbreviation: FOLFIRI ¼ leukovorin, 5-ﬂuorouracil, and oxaliplatin.
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54 -was excluded from the overall RAS WT analysis because a Köhne
prognostic category could not be established. Of the remaining RAS
WT/BRAF WT patients, 82, 211, and 83 were categorized as high,
medium, and low risk, respectively. In each of the 2 studies, baseline
demographic and disease characteristics were similar between the
treatment arms (see Supplemental Table 1 in the online version).
Overall RAS WT Analysis
For PRIME, data were fully mature for OS analysis (median
follow-up, 80 weeks), with 80 (94%), 212 (81%), and 65 (75%)
patients in the high, medium, and low risk categories, respectively,
having died at the time of analysis. At the time of analysis in the
20050181 study (median follow-up, 48 weeks), the number of
deaths was 73 (79%), 147 (63%), and 51 (55%), respectively.Clinical Colorectal Cancer March 2018In the RAS WT population, the PFS and OS HRs adjusted for
Köhne prognostic group favored panitumumab with chemotherapy
versus chemotherapy alone in both studies (Table 1). In PRIME, the
PFSHRwas 0.74 (95%CI, 0.62-0.90) and theOSHRwas 0.76 (95%
CI, 0.63-0.93). In the 20050181 study, the PFS and OS HRs were
0.78 (95%CI, 0.63-0.96) and 0.82 (95%CI, 0.64-1.04), respectively.
Outcome in Patients With RAS WTþBRAF WT/
Unknown mCRC
As in the RASWT population, the PFS and OS HRs adjusted for
Köhne prognostic group for patients with RAS WTþBRAF WT/
unknown mCRC favored panitumumab with chemotherapy versus
chemotherapy alone in both studies (Table 2; Figures 1 and 2; see
Supplemental Figures 3-6 in the online version). In PRIME, the
Salvatore Siena et alPFS HR was 0.74 (95% CI, 0.62-0.90) and the OS HR was 0.78
(95% CI, 0.64-0.95), whereas in the 20050181 study the PFS and
OS HRs were 0.80 (95% CI, 0.65-0.99) and 0.78 (95% CI, 0.61-
0.99), respectively. Median PFS and OS were numerically lower in
patients with BRAF MT mCRC than in any of the 3 risk categories
for patients with RASWTþBRAFWT/unknown mCRC (Table 2).
Results were similar when the 13 patients with unknown BRAF
status were excluded from the PRIME analysis (see Supplemental
Table 2 in the online version).
Discussion
The results of our analysis of PRIME study data conﬁrm that, in
patients with previously untreated mCRC, the prognostic scoring
system developed by Köhne and colleagues2 allows accurate risk
classiﬁcation in RAS WT and RAS WT þBRAF WT/unknown
mCRC. On the basis of data from the 20050181 study, we have
shown for the ﬁrst time that the Köhne score also allows risk clas-
siﬁcation in patients with RAS WT mCRC undergoing second-line
treatment. In both studies, Köhne categorization was particularly
successful for prediction of OS.
As previously reported,5-9 the presence of BRAF mutations was a
strong negative prognostic marker for outcome in both studies, and
such patients should be classiﬁed as high risk regardless of other
clinical parameters. Notably, the prevalence of BRAF mutations
varies between studies. In the triplet plus bevacizumab (TRIBE)
study, for example, 6% of patients had BRAF mutations,20
compared with 11% and 12%, respectively, in the present ana-
lyses of the PRIME and 20050181 studies. In contrast, 21% of
tumors in a Scandinavian registry had BRAF mutations.21 It should
also be noted that only 1 speciﬁc BRAF mutation (V600E) was
evaluated in our study, and it is possible that other BRAF mutations
would have different effects on outcomes.22,23
The overall efﬁcacy results of the PRIME and 20050181 studies
showed that PFS was improved by the additional use of pan-
itumumab with chemotherapy.8,17 OS was also improved by the
additional use of panitumumab with FOLFOX4 in the PRIME
study.12 In the 20050181 study, OS was numerically longer with
panitumumab with FOLFIRI than with FOLFIRI alone.24
Consistent with this, the HRs in these retrospective, exploratory
analyses suggest that panitumumab with chemotherapy might
provide PFS and OS beneﬁts versus chemotherapy alone in patients
with RAS WT and RAS WTþBRAF WT/unknown mCRC, overall
and across Köhne risk categories. Furthermore, a pilot study of ﬁrst-
line panitumumab monotherapy has shown the activity and toler-
ability of treatment in frail elderly patients with gastrointestinal
cancer classiﬁed as Köhne intermediate or high risk.25
The treatment guidelines issued by the European Society of
Medical Oncology in 2016 recommend that the aim of treatment
should be considered in management decisions for patients with
mCRC.1 The guidelines broadly deﬁne 2 patient categories: those
with potentially resectable disease or who need a rapid reduction in
tumor symptoms, for whom cytoreduction is the primary aim of
treatment, and those for whom the aim is disease control and
aggressive treatment is not necessary. The results of our analysis
suggest that panitumumab improves outcomes for both of these
patient subgroups: aggressive Köhne high-risk mCRC and nonag-
gressive Köhne low-risk mCRC.One of the strengths of the present work is that it is on the basis of
data from phase III, randomized, controlled trials, although these were
retrospective, post hoc analyses, and thus only descriptive data are re-
ported. The present work was also limited by the small patient numbers
in some subgroups. Further analysis using other prognostic scores, such
as the Groupe Coopérateur Multidisciplinaire en Oncologie model26
or the neutrophil/lymphocyte ratio,27 might be of interest. More
recently, side of disease of the primary tumor (left vs. right colon) has
emerged as a predictive and prognostic variable,28-31 which might be
driven by BRAF and other unfavorable mutations. Indeed, the per-
centage of patients with right-sided disease in the present analysis was
higher in the BRAFMT group than in any of the 3 Köhne prognostic
groups, which each had a similar percentage of patients with right-sided
disease. As a result of the small number of patients with right-sided
disease in the present study, however, we did not conduct any
further analysis of the prognostic effect of primary tumor location. In
the era of molecular subtyping—for example using mutational pro-
ﬁle,32 gene expression,33 or protein levels—it will be interesting to
correlate clinical subgroups to the underlying molecular alterations.
Finally, it has been suggested that the prognostic ability of the Köhne
model could be improved by incorporating baseline serum lactate de-
hydrogenase levels and quality of life measures of pain and mobility.34
Conclusion
In patients with untreated mCRC, Köhne prognostic score allows
accurate risk classiﬁcation in RAS WT and RAS WTþBRAF WT/
unknown mCRC, particularly with regard to OS. Thus, Köhne score
can be used as a stratiﬁcation factor in future clinical trials even when
targeted agents are used. Although the Köhne prognostic score was
developed for use in the ﬁrst-line mCRC setting, we show for the ﬁrst
time that it also allows risk classiﬁcation in patients with RAS WT
and RAS WT/BRAF WT mCRC undergoing second-line treatment.
BRAF mutations are also strongly negatively prognostic for outcome,
and patients with BRAF MT mCRC should be classiﬁed as high risk
regardless of other clinical parameters. The HRs in this retrospective,
exploratory analysis suggest that panitumumab with chemotherapy
might provide PFS and OS beneﬁts versus chemotherapy alone in
patients with RAS WT and RAS WTþBRAFWT/unknown mCRC,
overall and across risk categories. Further research is necessary to
investigate the relationship between Köhne prognostic category and
other known risk factors, such as primary tumor location.
Clinical Practice Points
 Survival outcomes in patients with metastatic colorectal cancer
(mCRC) differ widely depending on their disease characteristics
at the start of treatment.
 Choice of treatment is generally made on the basis of patient and
disease characteristics, treatment goal (e.g., resection or disease
control), and RAS status.
 Patients with mCRC can be divided into 3 Köhne prognostic
categories (high, medium and low risk) based on 4 baseline
clinical parameters.
 Mutations in the BRAF gene have been identiﬁed as a negative
prognostic marker in mCRC.
 Several phase III trials have demonstrated the efﬁcacy and
tolerability of the EGFR inhibitor panitumumab in patients with
RAS WT mCRC.Clinical Colorectal Cancer March 2018 - 55
Survival in RAS WT mCRC According to Köhne Category and BRAF Status
56 - In patients with previously untreated mCRC, Köhne prognostic
scoring allows accurate risk classiﬁcation in RAS WT and RAS
WTþBRAF WT/unknown mCRC.
 The Köhne score also allows risk classiﬁcation in patients with
RAS WT mCRC undergoing second-line treatment.
 Köhne categorisation was particularly successful for prediction of
OS.
 The presence of BRAF mutations was a strong negative prog-
nostic marker for outcome in both studies.
 Köhne score can be used as a stratiﬁcation factor in future clinical
trials even when targeted agents are used.
 Patients with BRAF MT mCRC should be classiﬁed as high risk
regardless of other clinical parameters.
 Panitumumab with chemotherapy may provide PFS and OS
beneﬁts versus chemotherapy alone in patients with RAS WT
and RAS WTþBRAF WT/unknown mCRC, overall and across
risk categories.Acknowledgments
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Supplemental Figure 3 KaplaneMeier Curves for Progression-Free Survival (PFS) in Patients in the PRIME Study With BRAF Wild
Type/Unknown Metastatic Colorectal Cancer (mCRC) Categorized as Köhne (A) High Risk, (B) Medium Risk, or
(C) Low Risk, and (D) for Patients With BRAF Mutant mCRC Overall in the Panitumumab With FOLFOX4 and
FOLFOX4-Alone Arms
48444036322824201612840
01237915223247
033356916193238
21:
2:
PFS (months)
0
20
40
60
80
100
K
ap
la
n-
M
ei
er
 e
st
im
at
e
No. at risk:
1: FOLFOX4 alone
2: Pmab + FOLFOX4
1: FOLFOX4 alone
2: Pmab + FOLFOX4
1: FOLFOX4 alone
2: Pmab + FOLFOX4
1: FOLFOX4 alone
2: Pmab + FOLFOX4
Censor indicated by vertical bar 
5
48444036322824201612840
3791520284170102131 0
81216223038476486115136
131:
2:
PFS (months)
0
20
40
60
80
100
K
ap
la
n-
M
ei
er
 e
st
im
at
e
No. at risk:
Censor indicated by vertical bar 
52 56 60 64
1
6
1
4
1
1
1
0
1
1
48444036322824201612840
5791214243741
6810141721364649
91:
2:
PFS (months)
0
20
40
60
80
100
K
ap
la
n-
M
ei
er
 e
st
im
at
e
No. at risk:
Censor indicated by vertical bar 
52 56
5
4
3
3
2
1
0
0
2
1
3620 28241612840
01451629
122791424
1:
2:
PFS (months)
0
20
40
60
80
100
K
ap
la
n-
M
ei
er
 e
st
im
at
e
No. at risk:
Censor indicated by vertical bar 
32 40
0
1
A
C
B
D
Abbreviations: FFXFOLFOX4 ¼ leukovorin, 5-ﬂuorouracil, and oxaliplatin; Pmab ¼ panitumumab; PRIME ¼ Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic
Colorectal Cancer to Determine Efﬁcacy.
Salvatore Siena et al
Clinical Colorectal Cancer March 2018 - 57.e2
Supplemental Figure 4 KaplaneMeier Curves for Progression-Free Survival (PFS) in Patients in the 20050181 Study With BRAF Wild
Type/Unknown Metastatic Colorectal Cancer (mCRC) Categorized as Köhne (A) High Risk, (B) Medium Risk, or
(C) Low Risk, and (D) for Patients With BRAF Mutant mCRC Overall in the Panitumumab and FOLFIRI and
FOLFIRI-Alone Arms
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Supplemental Figure 5 KaplaneMeier Curves for Overall Survival in Patients in the PRIME Study With BRAF Wild Type/Unknown
Metastatic Colorectal Cancer (mCRC) Categorized as Köhne (A) High Risk, (B) Medium Risk, or (C) Low Risk,
and (D) for Patients With BRAF Mutant mCRC Overall in the Panitumumab and FOLFOX4 and FOLFOX4-Alone
arms
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Supplemental Figure 6 KaplaneMeier Curves for Overall Survival in Patients in the 20050181 Study With BRAF Wild Type/Unknown
Metastatic Colorectal Cancer (mCRC) Categorized as Köhne (A) High Risk, (B) Medium Risk, or (C) Low Risk,
and (D) for Patients With BRAF Mutant mCRC Overall in the Panitumumab and FOLFIRI and FOLFIRI-Alone
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Supplemental Table 1 Baseline Demographic and Disease Characteristics in the PRIME and 20050181 Studies
Characteristic Panitumumab and FOLFOX4 (n [ 247) FOLFOX4 (n [ 248)
PRIME Study
Total
(n [ 247)
Risk Category
Total
(n [ 248)
Risk category
BRAF Mutant
(n [ 24)
High
(n [ 38)
Medium
(n [ 136)
Low
(n [ 49)
BRAF Mutant
(n [ 29)
High
(n [ 47)
Medium
(n [ 131)
Low
(n [ 41)
Sex, n (%)
Female 82 (33) 10 (42) 13 (34) 39 (29) 20 (41) 92 (37) 14 (48) 24 (51) 37 (28) 17 (41)
Male 165 (67) 14 (58) 25 (66) 97 (71) 29 (59) 156 (63) 15 (52) 23 (49) 94 (72) 24 (59)
Median Age (Range), Years 61 (27-81) 62 (44-80) 61 (37-78) 62 (30-81) 59 (27-77) 61 (24-82) 66 (37-76) 59 (31-79) 62 (24-80) 58 (27-82)
ECOG Performance Score, n (%)
0 146 (59) 10 (42) 20 (53) 81 (60) 35 (71) 135 (54) 17 (59) 12 (26) 78 (60) 28 (68)
1 87 (35) 11 (46) 8 (21) 54 (40) 14 (29) 97 (39) 11 (38) 23 (49) 50 (38) 13 (32)
2 14 (6) 3 (13) 10 (26) 1 (1) 0 (0) 16 (6) 1 (3) 12 (26) 3 (2) 0 (0)
Primary Tumor Diagnosis, n (%)
Colon 159 (64) 20 (83) 22 (58) 80 (59) 37 (76) 161 (65) 27 (93) 30 (64) 81 (62) 23 (56)
Rectum 88 (36) 4 (17) 16 (42) 56 (41) 12 (24) 87 (35) 2 (7) 17 (36) 50 (38) 18 (44)
Tumor Side, n (%)
Left 167 (68) 7 (29) 27 (71) 98 (72) 35 (71) 158 (64) 8 (28) 34 (72) 85 (65) 31 (76)
Right 38 (15) 13 (54) 2 (5) 17 (13) 6 (12) 49 (20) 16 (55) 3 (6) 26 (20) 4 (10)
Unknown 42 (17) 4 (17) 9 (24) 21 (15) 8 (16) 41 (17) 5 (17) 10 (21) 20 (15) 6 (15)
Sites of Metastases, n (%)
Liver and other 164 (66) 18 (75) 34 (89) 112 (82) 0 (0) 170 (69) 19 (66) 42 (89) 109 (83) 0 (0)
Liver only 48 (19) 1 (4) 1 (3) 1 (1) 45 (92) 41 (17) 4 (14) 0 (0) 1 (1) 36 (88)
Other only 35 (14) 5 (21) 3 (8) 23 (17) 4 (8) 37 (15) 6 (21) 5 (11) 21 (16) 5 (12)
Previous Adjuvant
Chemotherapy, n (%)
Yes 205 (83) 20 (83) 33 (87) 107 (79) 45 (92) 211 (85) 23 (79) 44 (94) 107 (82) 37 (90)
No 42 (17) 4 (17) 5 (13) 29 (21) 4 (8) 37 (15) 6 (21) 3 (6) 24 (18) 4 (10) Salvatore
Siena
et
al
ClinicalColorectalCancer
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2018 -57.e6
20050181 Study
Panitumumab and FOLFIRI FOLFIRI
Total
(n [ 207)
Risk Category
Total
(n [ 213)
Risk Category
BRAF Mutant
(n [ 21)
High
(n [ 38)
Medium
(n [ 111)
Low
(n [ 37)
BRAF Mutant
(n [ 23)
High
(n [ 44)
Medium
(n [ 100)
Low
(n [ 46)
Sex, n (%)
Female 72 (35) 8 (38) 15 (39) 42 (38) 7 (19) 73 (34) 10 (43) 19 (43) 29 (29) 15 (33)
Male 135 (65) 13 (62) 23 (61) 69 (62) 30 (81) 140 (66) 13 (57) 25 (57) 71 (71) 31 (67)
Median Age (Range), Years 60 (28-81) 61 (42-76) 58 (37-78) 60 (36-81) 65 (28-79) 60 (33-85) 62 (40-72) 60 (33-85) 61 (41-82) 60 (35-79)
ECOG Performance Score, n (%)
0 102 (49) 5 (24) 13 (34) 61 (55) 23 (62) 104 (49) 7 (30) 17 (39) 58 (58) 22 (48)
1 94 (45) 14 (67) 16 (42) 50 (45) 14 (38) 94 (44) 13 (57) 18 (41) 39 (39) 24 (52)
2 11 (5) 2 (10) 9 (24) 0 (0) 0 (0) 15 (7) 3 (13) 9 (20) 3 (3) 0 (0)
Primary Tumor Diagnosis, n (%)
Colon 118 (57) 13 (62) 23 (61) 61 (55) 21 (57) 148 (69) 21 (91) 30 (68) 70 (70) 27 (59)
Rectum 89 (43) 8 (38) 15 (39) 50 (45) 16 (43) 65 (31) 2 (9) 14 (32) 30 (30) 19 (41)
Tumor Side, n (%)
Left 150 (72) 7 (33) 28 (74) 86 (77) 29 (78) 148 (69) 4 (17) 31 (70) 74 (74) 39 (85)
Right 31 (15) 9 (43) 3 (8) 17 (15) 2 (5) 39 (18) 13 (57) 7 (16) 16 (16) 3 (7)
Unknown 26 (13) 5 (24) 7 (18) 8 (7) 6 (16) 26 (12) 6 (26) 6 (14) 10 (10) 4 (9)
Sites of Metastases, n (%)
Liver and other 140 (68) 17 (81) 31 (82) 92 (83) 0 (0) 134 (63) 14 (61) 40 (91) 80 (80) 0 (0)
Liver only 37 (18) 3 (14) 2 (5) 0 (0) 32 (86) 49 (23) 4 (17) 0 (0) 3 (3) 42 (91)
Other only 30 (14) 1 (5) 5 (13) 19 (17) 5 (14) 30 (14) 5 (22) 4 (9) 17 (17) 4 (9)
Previous Adjuvant
Chemotherapy, n (%)
Yes 157 (76) 15 (71) 31 (82) 83 (75) 28 (76) 181 (85) 19 (83) 43 (98) 78 (78) 41 (89)
No 45 (22) 5 (24) 5 (13) 27 (24) 8 (22) 31 (15) 3 (13) 1 (2) 22 (22) 5 (11)
Missing 5 (2) 1 (5) 2 (5) 1 (<1) 1 (3) 1 (<1) 1 (4) 0 (0) 0 (0) 0 (0)
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; FOLFIRI ¼ leukovorin, 5-ﬂuorouracil, and irinotecan; FOLFOX4 ¼ leukovorin, 5-ﬂuorouracil, and oxaliplatin; PRIME ¼ Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal
Cancer to Determine Efﬁcacy.
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Supplemental Table 2 Progression-Free Survival and OS in BRAF Wild Type mCRC Categorized According to Köhne Prognostic
Category, and BRAF Mutant mCRC in the PRIME Study
Risk Category
KaplaneMeier Median PFS, Months (95% CI) Kaplan-Meier Median OS, Months (95% CI)
Panitumumab With
FOLFOX4 FOLFOX4
Panitumumab With
FOLFOX4 FOLFOX4
BRAF Wild Type
High n ¼ 36
7.1 (5.7-13.8)
n ¼ 47
7.8 (5.3-11.4)
n ¼ 36
15.0 (9.7-21.7)
n ¼ 47
15.1 (10.6-20.2)
HR, 0.82; 95% CI, 0.52-1.30 HR, 0.89; 95% CI, 0.56-1.40
Medium n ¼ 134
12.6 (9.7-15.4)
n ¼ 125
9.2 (7.3-10.6)
n ¼ 134
30.8 (25.4-36.3)
n ¼ 125
22.6 (17.8-27.2)
HR, 0.63; 95% CI, 0.48-0.82 HR, 0.67; 95% CI, 0.51-0.88
Low n ¼ 46
10.9 (9.4-21.3)
n ¼ 41
9.9 (7.2-12.9)
n ¼ 46
40.7 (26.6-51.7)
n ¼ 41
35.2 (23.1-46.8)
HR, 0.78; 95% CI, 0.49-1.24 HR, 0.72; 95% CI, 0.44-1.19
BRAF Mutant
Overall n ¼ 24
6.0 (3.5-10.7)
n ¼ 29
5.4 (3.3-6.2)
n ¼ 24
10.4 (5.6-18.9)
n ¼ 29
9.2 (7.5-15.7)
HR, 0.74; 95% CI, 0.42-1.29 HR, 0.97; 95% CI, 0.55-1.69
Abbreviations: FOLFOX4 ¼ leukovorin, 5-ﬂuorouracil, and oxaliplatin; HR ¼ hazard ratio; mCRC ¼ metastatic colorectal cancer; OS ¼ overall survival; PFS ¼ progression-free survival; PRIME ¼
Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efﬁcacy.
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